Cargando…
Successful Treatment of Metastatic Anal Canal Adenocarcinoma with mFOLFOX6 + Bevacizumab
Anal canal adenocarcinoma is a relatively rare malignancy without established diagnostic and treatment criteria. Case reports of chemotherapy for anal canal adenocarcinoma with distant metastasis are limited, and there is no convincing evidence for treatment effectiveness. A 62-year-old man complain...
Autores principales: | Matsunaga, Mototsugu, Miwa, Keisuke, Oka, Yosuke, Nagasu, Sachiko, Sakaue, Takahiko, Fukahori, Masaru, Ushijima, Tomoyuki, Akagi, Yoshito |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881273/ https://www.ncbi.nlm.nih.gov/pubmed/27239180 http://dx.doi.org/10.1159/000446107 |
Ejemplares similares
-
mFOLFOX6 Chemotherapy after Resection of Anal Canal Mucinous Adenocarcinoma
por: Matsunaga, Mototsugu, et al.
Publicado: (2016) -
Successful Treatment with S-1 and Oxaliplatin Combination Therapy in an Elderly Patient with Metastatic Colorectal Cancer Initially Presenting with Membranous Nephropathy
por: Matsunaga, Mototsugu, et al.
Publicado: (2015) -
Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
por: Cunningham, D, et al.
Publicado: (2013) -
Case report: Changes in serum bevacizumab concentration in a hemodialysis patient with unresectable colorectal cancer treated with FOLFIRI plus bevacizumab
por: Tanaka, Toshimitsu, et al.
Publicado: (2022) -
Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial
por: Takahashi, Takao, et al.
Publicado: (2022)